Medivir
  • About us
  • Our projects
  • R&D
  • Investors
  • News and media
  • Connect
  • Test
  • Svenska
About us
  • Medivir in brief
  • Business concept & Strategy
  • Leadership
    • Management team
    • Board of Directors
  • History
  • EFPIA Disclosure
Our projects
  • Projects for licensing
    • MIV-818
  • Proprietary
    • Remetinostat
    • Birinapant
    • MIV-711
  • Partnerships
    • MIV-802
    • Xerclear®
  • Publications
R&D
  • Area of expertise
  • About cancer
Investors
  • Stock information
  • Reports
    • Financial reports 2018
    • Financial reports 2017
    • Financial reports 2016
    • Financial reports 2015
    • Financial reports 2014
    • Financial reports 2013
    • Financial Reports 2012
  • Presentations
    • Presentations 2019
    • Presentations 2018
    • Presentations 2017
    • Presentations 2016
    • Presentations 2015
    • Presentations 2014
    • Presentations 2013
    • Presentations 2012
    • Presentations 2011
    • Presentations 2010
  • Press releases
    • Press release
    • Subscribe
  • Press releases - old
  • Events
    • Test event
  • Corporate Governance
  • Annual General Meeting
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
News and media
  • Press releases
  • Media bank
Connect
  • Connect with Medivir
  • Partner with Medivir
Test
Search
Address

Medivir AB
Box 1086
SE-141 22 Huddinge

Phone +46 (0)8 546 831 00 Email info@medivir.com
Our privacy policy

Read more

 

Uli Hacksell

President and CEO

+46 8 5468 3100 uli.hacksell@medivir.com
 

Erik Björk

Chief Financial Officer

+46 (0)72 228 2831 erik.bjork@medivir.com